Innovus Pharmaceuticals (OTCMKTS:INNVD – Get Free Report) and iBio (NASDAQ:IBIO – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.
Earnings and Valuation
This table compares Innovus Pharmaceuticals and iBio”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Innovus Pharmaceuticals | $23.99 million | 0.00 | -$8.28 million | ($4.16) | N/A |
| iBio | $400,000.00 | 214.87 | -$18.38 million | ($0.58) | -2.98 |
Profitability
This table compares Innovus Pharmaceuticals and iBio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Innovus Pharmaceuticals | -34.51% | -682.54% | -78.57% |
| iBio | N/A | -53.86% | -46.48% |
Analyst Recommendations
This is a breakdown of recent recommendations for Innovus Pharmaceuticals and iBio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Innovus Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
| iBio | 1 | 0 | 4 | 3 | 3.13 |
iBio has a consensus target price of $5.00, suggesting a potential upside of 189.02%. Given iBio’s stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Innovus Pharmaceuticals.
Insider & Institutional Ownership
10.4% of Innovus Pharmaceuticals shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of iBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Innovus Pharmaceuticals has a beta of 2.89, meaning that its share price is 189% more volatile than the S&P 500. Comparatively, iBio has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Summary
iBio beats Innovus Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Innovus Pharmaceuticals
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
About iBio
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
